Skip to main content

Advertisement

SpringerLink
Log in

Reconstituted Botulinum Type A Neurotoxin: Clinical Efficacy After Long-Term Freezing Before Use

  • Published:
Aesthetic Plastic Surgery Aims and scope Submit manuscript

Abstract

Botulinum neurotoxin type A (BoNT/A) is injected into muscles of facial expression for treatment of facial wrinkles. Manufacturers’ recommendations state that the product should be used within 4 h of reconstitution to prevent loss of effectiveness. A prospective study was undertaken to evaluate the effectiveness of reconstituted BoNT/A when preserved in a frozen state for up to 6 months, as compared with nonfrozen BoNT/A used within 4 h after reconstitution. Treatment of 118 sites in 80 patients was performed and evaluated for aesthetic efficacy. Excellent results were observed in 94.8% of sites treated with nonfrozen BoNT/A and in 93.3% of the sites treated with frozen and thawed BoNT/A (p = 1). Minor side effects were rare and transient in both groups. In contrast to common belief, reconstituted BoNT/A may be frozen, thawed, and injected without losing its potency for up to 6 months, with efficacy equivalent to that of freshly prepared BoNT/A.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Allergan, Inc: Botox cosmetic (botulinum toxin type A) purified neurotoxin complex [package insert]. Allergan, Inc., Irvine, CA, USA

  2. Arthurs B, Flanders M, Codere F, Gauthier S, Dresner S, Stone L: Treatment of blepharospasm with medication, surgery, and type A botulinum toxin. Can J Ophthalmol 22:24–28, 1987

    PubMed  CAS  Google Scholar 

  3. Fagien S: Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: Adjunctive use in facial aesthetic surgery. Plast Reconstr Surg 112:40s–52s, 2003

    Article  Google Scholar 

  4. Freeman A (principal investigator): A randomized, multicenter, double-blind, placebo-controlled study of intramuscular BOTOX (botulinum toxin type A) purified neurotoxin complex for the treatment of cervical dystonia. Data on file. Allergan, Inc., Irvine, CA, USA, June 1995–June 1998

  5. Guerrissi JO: Intraoperative injection of botulinum toxin A into the orbicularis oculi muscle for the treatment of crow’s feet. Plast Reconstr Surg 112:161s–163s, 2003

    Article  PubMed  Google Scholar 

  6. Kim EJ, Ramirez AL, Reeck JB, Maas CS: The role of botulinum type B (Myobloc) in the treatment of hyperkinetic facial lines. Plast Reconst Surg 112:88s–93s, 2003z

    Article  PubMed  Google Scholar 

  7. Koriazova LK, Montal M: Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol 10:13–18, 2003

    Article  PubMed  CAS  Google Scholar 

  8. Niamtu J: Cosmetic oral and maxillofacial surgery options. J Am Dent Assoc 131:756–764, 2000

    PubMed  Google Scholar 

  9. Parsa FD: How to avoid eyelid ptosis when injecting botulinum toxin into the corrugators. Plast Reconstr Surg 105:1564–1565, 2000

    Article  PubMed  CAS  Google Scholar 

  10. Preacher KJ, Briggs NE. Calculation for Fisher’s exact test: An interactive calculation tool for Fisher’s exact probability test for 2 × 2 tables (computer software). Accessed 25 July 2006 at http://www.unc.edu/∼preacher/fisher/fisher.htm

  11. Rohrich RJ, Janis JE, Fagien S, Stuzin JM: The cosmetic use of botulinum toxin. Plast Reconstr Surg 112:177s–187s, 2003

    Article  PubMed  Google Scholar 

  12. Singh BR: Critical aspects of bacterial protein toxins. Adv Exp Med Biol 391:63–84, 1996

    PubMed  CAS  Google Scholar 

  13. Zhou Y, Singh BR: Cloning, high-level expression, single-step purification, and binding activity of His6-tagged recombinant type B botulinum neurotoxin heavy chain transmembrane and binding domain. Protein Expr Purif 34:8–16, 2004

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments.

The authors acknowledge the diligence of Mrs. Lisa Coehlo in assisting with the preparation of this article. The authors have no financial interest in or support from Allergan, Inc. or other manufacturers.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Seton Hall University School of Graduate Medical Education, St. Francis Medical Center, Trenton, NJ, USA

    Alan A. Parsa M.D.

  2. Department of Surgery, Division of Plastic Surgery, John A. Burns School of Medicine, University of Hawaii, Queen’s Physician’s Office Building II, 1329 Lusitana Street, Suite 807, Honolulu, HI, 96813, USA

    Kevin D. Lye M.D. & Fereydoun Don Parsa M.D., F.A.C.S.

Authors
  1. Alan A. Parsa M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin D. Lye M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fereydoun Don Parsa M.D., F.A.C.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fereydoun Don Parsa M.D., F.A.C.S..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parsa, A.A., Lye, K.D. & Parsa, F.D. Reconstituted Botulinum Type A Neurotoxin: Clinical Efficacy After Long-Term Freezing Before Use. Aesth Plast Surg 31, 188–191 (2007). https://doi.org/10.1007/s00266-006-0161-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00266-006-0161-1

Keywords

Search

Navigation